Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2

BACKGROUND: Ramucirumab is indicated for patients with advanced hepatocellular carcinoma (HCC) and α-fetoprotein (AFP) ≥400 ng/mL following sorafenib. Here, we prospectively studied ramucirumab following non-sorafenib systemic therapies. MATERIALS AND METHODS: This open-label, non-comparative cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Finn, Richard S, Yau, Thomas, Hsu, Chih-Hung, De Toni, Enrico N, Goyal, Lipika, Galle, Peter R, Qin, ShuKui, Rao, Sujata, Sun, Fangfang, Wang, Chunxiao, Widau, Ryan C, Zhu, Andrew X
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249425/
https://www.ncbi.nlm.nih.gov/pubmed/36190331
http://dx.doi.org/10.1093/oncolo/oyac183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249425/
https://www.ncbi.nlm.nih.gov/pubmed/36190331
http://dx.doi.org/10.1093/oncolo/oyac183

Ejemplares similares